Supplementary Figure 1 from A Novel Regulatory Mechanism of Pim-3 Kinase Stability and Its Involvement in Pancreatic Cancer Progression

Fei Zhang,Bin Liu,Zhen Wang,Xian-Jun Yu,Quan-Xing Ni,Wen-Tao Yang,Naofumi Mukaida,Ying-Yi Li

DOI: https://doi.org/10.1158/1541-7786.22510524

2023-01-01

Abstract:PDF - 59KB, Quantitative RT-PCR analyses for Pim-1, Pim-2, and Pim-3.

What problem does this paper attempt to address?

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

Quan Qi,Yuefen Pan,Shuwen Han,Haihong Liao,Yizhen Jiang,Junjun Shen,Liping Zhong,Xian Wang,Jie Chen

DOI: https://doi.org/10.1002/ar.24024

2018-01-01

The Anatomical Record

Abstract:ABSTRACTColorectal cancer (CRC) is one of the common human malignancies. Discovery and identification of novel therapeutic target is imperative to improve the prognosis of CRC patients. As a member of the PIM family, PIM3 has been found to be overexpressed in a variety of cancerous tumors. In this study, we evaluated the expression of PIM3 in CRC tissues and analyzed the role of PIM3 in CRC. Our results showed that PIM3 expression was significantly higher in CRC tissues compared with adjacent noncancerous tissues. The PIM3 expression level was found to be correlated with advanced disease stage and lymph node metastasis. Moreover, PIM3 was found to be able to predict poor prognosis in CRC patients as an independent factor. In vitro studies also showed that knockdown of PIM3 exhibited inhibitory effect on cell growth, promoted cell apoptosis and dampened invasive capability of HCT116 and SW620 cells. Moreover, PIM3 knockdown was able to delay tumor growth and suppress lung metastasis in xenograft model. Our results indicated that PIM3 is a potential therapeutic target for CRC. Anat Rec, 302:1552–1560, 2019. © 2018 American Association for Anatomy
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:<p>PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.</p>
Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Kun Guo,Jiujie Cui,Ming Quan,Dacheng Xie,Zhiliang Jia,Daoyan Wei,Liang Wang,Yong Gao,Qingyong Ma,Keping Xie

DOI: https://doi.org/10.1158/1078-0432.22462092.v1

2023-01-01

Abstract:Supplementary Figure S1. Expression of MSI2 in PDAC specimens. Supplementary Figure S2. Localization of MSI2 in PDAC cells. Supplementary Figure S3. Co-expression of MSI2 and KLF4 in colon and gastric cancer cells.
Supplementary Figure 1 from Eif4b Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by <i>abl</i> Oncogenes

Jianling Yang,Jun Wang,Ke Chen,Guijie Guo,Ruijiao Xi,Paul B. Rothman,Douglas Whitten,Lianfeng Zhang,Shile Huang,Ji-Long Chen

DOI: https://doi.org/10.1158/0008-5472.22398198

2023-01-01

Abstract:PDF - 21K, Pim-3 has little effect on eIF4B phosphorylation at Ser422.
Supplementary Figure 1 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects

Qie Guo,Peixiang Lan,Xin Yu,Qiuju Han,Jian Zhang,Zhigang Tian,Zhen Cai

DOI: https://doi.org/10.1158/1535-7163.22499674.v1

2023-01-01

Abstract:PDF - 44K, Figure S1. The expression of Pim-3 in mouse hepatoma cell lines and human hepatocellular carcinoma tissues. The expression of Pim-3 in murine hepatoma cell lines H22 and Hepa1-6 and the normal liver cell line BNL.CL2 as measured by semi-quantitative RT-PCR (A) and Western blotting (B). The expression of Pim-3 in human hepatocellular carcinoma tissues (T) and nontumor tissues (N) detected by real-time PCR (C) and Western blotting (D).
Figure S3 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Fang Wang,Xiaomei Qi,Ryan Wertz,Matthew Mortensen,Catherine Hagen,John Evans,Yuri Sheinin,Mark James,Pengyuan Liu,Susan Tsai,James D. Thomas,Alexander C. Mackinnon,Michael B. Dwinell,Charles R. Myers,Ramón Bartrons,Liwu Fu,Guan Chen

DOI: https://doi.org/10.1158/0008-5472.22423431.v1

2023-01-01

Abstract:Figure S3. Pancreatic p38ÃƒÅ½Ã,Â³ KO inhibits pancreatic cancer metastasis and decreases p-PFKFB3, PFKFB3, GLUT2, inflammatory cytokine expression and suppresses metabolic and other pancreatic cancer pathways in metastatic and/or primary Pdac.
Supplementary Figures with Figure Legends from PIN1 Maintains Redox Balance Via the C-Myc/nrf2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells

Chen Liang,Si Shi,Mingyang Liu,Yi Qin,Qingcai Meng,Jie Hua,Shunrong Ji,Yuqing Zhang,Jingxuan Yang,Jin Xu,Quanxing Ni,Min Li,Xianjun Yu

DOI: https://doi.org/10.1158/0008-5472.22421300

2023-01-01

Abstract:Supplementary Figure 1 showed PIN1 promotes the growth of pancreatic cancer cells in vitro. Supplementary Figure 2 showed PIN1 affects the expression of the expression of mitochondrial proteins. Supplementary Figure 3 showed Immunoblot analysis of anti-oxidative genes expression in pancreatic cancer cells with silencing of PIN1 expression. Supplementary Figure 4 showed c-Myc is involved in PIN1-induced malignant potential. Supplementary Figure 5 showed the percentage of NRF2-positive cells with different grades of PIN1 expression in the PDAC tissue microarray.
Pim-3 is Expressed in Endothelial Cells and Promotes Vascular Tube Formation

Peng Zhang,Hanqin Wang,Xinwen Min,Yinfang Wang,Jie Tang,Jishun Cheng,Dongfeng Li,Xin Chen,Fanjun Cheng,Nanping Wang,Handong Yang

DOI: https://doi.org/10.1002/jcp.21733

2009-01-01

Journal of Cellular Physiology

Abstract:Pim-3 is a member of proto-oncogene Pim family that encodes serine/threonine kinases. Pim proteins regulate both apoptosis and cellular metabolism by phosphorylating their substrates. Here, we report for the first time that Pim-3 is highly expressed at mRNA and protein levels in endothelial cells (ECs). We found that Pim-3 is concentrated at the cellular lamellipodia and co-localized with focal adhesion kinase (FAK). Pim-3 was dispersed from lamellipodia when ECs were treated with cytochalasin D, an inhibitor of actin polymerization. In addition, small-interfering RNA (siRNA)-mediated gene knockdown of Pim-3 significantly impaired EC spreading, migration, and proliferation, leading to a reduction in tube-like structure formation in a Matrigel assay. These results provide the novel evidence that Pim-3 plays an essential role in EC spreading and migration, suggesting that Pim-3 may be an important molecular target for the development of small-molecule inhibitors of angiogenesis. J. Cell. Physiol. 220: 82-90, 2009. (C) 2009 Wiley-Liss, Inc.
Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Dongping Wei,Leslie A. Parsels,David Karnak,Mary A. Davis,Joshua D. Parsels,Amanda C. Marsh,Lili Zhao,Jonathan Maybaum,Theodore S. Lawrence,Yi Sun,Meredith A. Morgan

DOI: https://doi.org/10.1158/1078-0432.22450100

2023-01-01

Abstract:PDF file - 52K, LB100 causes an increase in pHistone H3 positive cells.
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. Garcia,John L. Langowski,Yingyun Wang,Min Chen,Joseph Castillo,Christie Fanton,Marjorie Ison,Tatiana Zavorotinskaya,Yumin Dai,Jing Lu,Xiao-Hong Niu,Stephen Basham,Julie Chan,Jianjun Yu,Michael Doyle,Paul Feucht,Robert Warne,Jamie Narberes,Tiffany Tsang,Christine Fritsch,Audrey Kauffmann,Estelle Pfister,Peter Drueckes,Joerg Trappe,Christopher Wilson,Wooseok Han,Jiong Lan,Gisele Nishiguchi,Mika Lindvall,Cornelia Bellamacina,J. Alex Aycinena,Richard Zang,Jocelyn Holash,Matthew T. Burger

DOI: https://doi.org/10.1158/1078-0432.22452158

2023-01-01

Abstract:PDF file - 346KB, Supplementary Figure 1. Normal vs. Tumor expression of PIM kinases mRNA across 17 tissue types. Supplementary Figure 2. Comparison of LGB321 on-target activity vs. Previously described pan-PIM inhibitor. Supplementary Figure 3. KINOMESCANTM of 1 mu M LGB321. Supplementary Figure 4. Biochemical and cellular selectivity of the LGB321 PIM inhibitor series towards GSK3 beta. Supplementary Figure 5. LGB321 does not inhibit EGFR signaling in HCC1954 cells. Supplementary Table 1. Sensitivity to LGB321 and Erlotinib of Lung Cells in the CCLE. Supplementary Table 2. Sensitivity to LGB321 of hematological malignacies cell lines.
Figure S2 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Fang Wang,Xiao-Mei Qi,Ryan Wertz,Matthew Mortensen,Catherine Hagen,John Evans,Yuri Sheinin,Michael James,Pengyuan Liu,Susan Tsai,James Thomas,Alexander Mackinnon,Michael Dwinell,Charles R. Myers,Ramon Bartrons Bach,Liwu Fu,Guan Chen

DOI: https://doi.org/10.1158/0008-5472.22423434.v1

2023-01-01

Abstract:Figure S2. p38ÃƒÅ½Ã,Â³ knockout (KO) decreases p-Rb and CDK6 protein levels, slows G1/S transition, and inhibits cell growth, migration, and invasion in KPC cells, but lacks significant effects in PanIN lesions in KC mice.
PIM1 kinase and its diverse substrate in solid tumors

Rituparna Choudhury,Chandan Kumar Bahadi,Ipsa Pratibimbita Ray,Pragyanshree Dash,Isha Pattanaik,Suman Mishra,Soumya R. Mohapatra,Srinivas Patnaik,Kumar Nikhil

DOI: https://doi.org/10.1186/s12964-024-01898-y

IF: 7.525

2024-11-02

Cell Communication and Signaling

Abstract:The PIM kinase family, consisting of PIM1, PIM2, and PIM3, is a group of serine/threonine protein kinases crucial for cellular growth, immunoregulation, and oncogenesis. PIM1 kinase is often overexpressed in solid and hematopoietic malignancies, promoting cell survival, proliferation, migration, and senescence by activating key genes. In vitro and in vivo studies have established the oncogenic potential of PIM1 kinases. These kinases have been implicated in tumor progression, metastasis, and resistance to chemotherapy, underscoring their potential as a therapeutic target for cancer therapy. This review delves into the intricate molecular mechanisms through which PIM1 interacts with specific substrates in different tumor tissues, leading to diverse outcomes in various human cancers. Over the past decade, the inhibition of PIM1 in cancers has garnered significant attention as a potential standalone treatment. Various in vitro, in vivo, and early clinical trial data have provided support for this approach to varying extents. Novel compounds that inhibit PIM1 kinase have shown effectiveness and a favorable toxicity profile in preclinical studies. Several of these substances are now being studied in clinical trials due to their promising outcomes. This article provides a thorough examination of the PIM1 kinase pathways and the recent advancements in producing PIM1 kinase inhibitors for the treatment of cancer.

cell biology
Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Fang Wang,Xiao-Mei Qi,Ryan Wertz,Matthew Mortensen,Catherine Hagen,John Evans,Yuri Sheinin,Michael James,Pengyuan Liu,Susan Tsai,James Thomas,Alexander Mackinnon,Michael Dwinell,Charles R. Myers,Ramon Bartrons Bach,Liwu Fu,Guan Chen

DOI: https://doi.org/10.1158/0008-5472.22423425

2023-01-01

Abstract:Figure S5. PFD decreases p-PFKFB3, PFKFB3 and Glut2 expression in primary KPC tumors and suppresses allograft growth of KPC, but not KPC/p38ÃƒÅ½Ã,Â³ KO tumor, in association with decreased Ki67, p-PFKFB3, PFKFB3 and ÃƒÅ½Ã,Â±-SMA expression in tumor tissues.
Essential Contribution Of Ets-1 To Constitutive Pim-3 Expression In Human Pancreatic Cancer Cells

Ying-Yi Li,Yu Wu,Koichi Tsuneyama,Tomohisa Baba,Naofumi Mukaida

DOI: https://doi.org/10.1111/j.1349-7006.2008.01059.x

IF: 5.7

2009-01-01

Cancer Science

Abstract:We previously demonstrated that the proto-oncogene Pim-3 with serine/threonine kinase activity was aberrantly expressed in cancer cells but not in the normal cells of the pancreas. In order to elucidate the molecular mechanism underlying aberrant Pim-3 expression in pancreatic cancer cells, we constructed luciferase expression vectors linked to 5'-flanking deletion mutants of the human Pim-3 gene and transfected human pancreatic cancer cells with the resultant vectors. The region up to -264 bp was essential for constitutive Pim-3 gene expression, and the mutation in the Ets-1 binding site (between -216 and -211 bp) reduced luciferase activities. Moreover, Ets-1 mRNA and protein were constitutively expressed together with Pim-3 in human pancreatic cancer cell lines. Chromatin immunoprecipitation assay demonstrated constitutive binding of Ets-1 to the 5'-flanking region of human Pim-3 gene between -249 and -183 bp. Pim-3 promoter activity and its protein expression were induced by transfection with wild type-Ets-1 and were reduced by transfection with dominant negative-Ets-1 or Ets-1 small-interfering RNA (siRNA). Furthermore, dominant negative-Ets-1 and Ets-1 siRNA reduced the amount of Bad phosphorylated at its Ser(112) and induced apoptosis, when they were transfected into human pancreatic cancer cells. Finally, Pim-3 cDNA transfection reversed Ets-1 siRNA-induced increase in apoptosis and decrease in Bad phosphorylation at its Ser(112). These observations would indicate that the transcription factor Ets-1 can induce aberrant Pim-3 expression and subsequently prevent apoptosis in human pancreatic cancer cells. (Cancer Sci 2009; 100: 396-404).
Pim-3 Contributes to Radioresistance Through Regulation of the Cell Cycle and DNA Damage Repair in Pancreatic Cancer Cells

Xiang-Yuan Chen,Zhen Wang,Bei Li,Ying-Jian Zhang,Ying-Yi Li

DOI: https://doi.org/10.1016/j.bbrc.2016.03.099

IF: 3.1

2016-01-01

Biochemical and Biophysical Research Communications

Abstract:Resistance of cancer cells to chemoradiotherapy is a major clinical problem in pancreatic cancer treatment. Therefore, understanding the molecular basis of cellular resistance and identifying novel targets are essential for improving treatment efficacy for pancreatic cancer patients. Previous studies have demonstrated a significant role for Pim-3 in pancreatic cancer survival against gemcitabine-induced genotoxic stress. Here, we observed that radiation treatment enhanced Pim-3 expression in human pancreatic cancer cells in vitro. Stable overexpression of Pim-3 in pancreatic cancer cells significantly protected cells against radiation treatment by attenuating G2/M phase cell cycle arrest and DNA damage response. Silencing of Pim-3 expression significantly elevated the phosphorylation of histone variant H2AX, a marker of DNA double strand breaks, and decreased the activation of ataxia-telangiectasia-mutated (ATM) kinase, along with its downstream targets, eventually enhancing the radiosensitivity of human pancreatic cancer cells in vitro and in vivo. Hence, we demonstrated a novel function for Pim-3 in human pancreatic cancer cell survival against radiation. Targeting Pim-3 may be a promising way to improve treatment efficacy in combination with radiotherapy in human pancreatic cancer.
Supplementary Figure Legends from Eif4b Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Abl Oncogenes

Jianling Yang,Jun Wang,Ke Chen,Guijie Guo,Ruijiao Xi,Paul B. Rothman,Douglas Whitten,Lianfeng Zhang,Shile Huang,Ji-Long Chen

DOI: https://doi.org/10.1158/0008-5472.22398183

2023-01-01

Abstract:PDF - 32K, Legend for Supplementary Figures S1-S5.
PIM3 Kinase: A Promising Novel Target in Solid Cancers

Pinar Atalay,Bulent Ozpolat

DOI: https://doi.org/10.3390/cancers16030535

2024-01-27

Cancers

Abstract:PIM3 (provirus-integrating Moloney site 3) is a serine/threonine kinase and belongs to the PIM family (PIM1, PIM2, and PIM3). PIM3 is a proto-oncogene that is frequently overexpressed in cancers originating from endoderm-derived tissues, such as the liver, pancreas, colon, stomach, prostate, and breast cancer. PIM3 plays a critical role in activating multiple oncogenic signaling pathways promoting cancer cell proliferation, survival, invasion, tumor growth, metastasis, and progression, as well as chemo- and radiation therapy resistance and immunosuppressive microenvironment. Genetic inhibition of PIM3 expression suppresses in vitro cell proliferation and in vivo tumor growth and metastasis in mice with solid cancers, indicating that PIM3 is a potential therapeutic target. Although several pan-PIM inhibitors entered phase I clinical trials in hematological cancers, there are currently no FDA-approved inhibitors for the treatment of patients. This review provides an overview of recent developments and insights into the role of PIM3 in various cancers and its potential as a novel molecular target for cancer therapy. We also discuss the current status of PIM-targeted therapies in clinical trials.

oncology
Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Li Lin,Brian Hutzen,Mingxin Zuo,Sarah Ball,Stephanie Deangelis,Elizabeth Foust,Bulbul Pandit,Michael A. Ihnat,Satyendra S. Shenoy,Samuel Kulp,Pui-Kai Li,Chenglong Li,James Fuchs,Jiayuh Lin

DOI: https://doi.org/10.1158/0008-5472.22387140.v1

2023-01-01

Abstract:Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Supplementary Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Dan Wang,Kun Yan,Hongxing Yu,Haocheng Li,Wei Zhou,Yaqiang Hong,Shuning Guo,Yi Wang,Cheng Xu,Changcun Pan,Yujie Tang,Nian Liu,Wei Wu,Liwei Zhang,Qiaoran Xi

DOI: https://doi.org/10.1158/0008-5472.25224448

2024-01-01

Abstract:Supplementary Figures 1-7; Supplementary Tables 1-8

Supplementary Figure 1 from A Novel Regulatory Mechanism of Pim-3 Kinase Stability and Its Involvement in Pancreatic Cancer Progression

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Supplementary Figure 1 from Eif4b Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by &lt;i&gt;abl&lt;/i&gt; Oncogenes

Supplementary Figure 1 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects

Figure S3 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Figures with Figure Legends from PIN1 Maintains Redox Balance Via the C-Myc/nrf2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells

Pim-3 is Expressed in Endothelial Cells and Promotes Vascular Tube Formation

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Figure S2 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

PIM1 kinase and its diverse substrate in solid tumors

Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Essential Contribution Of Ets-1 To Constitutive Pim-3 Expression In Human Pancreatic Cancer Cells

Pim-3 Contributes to Radioresistance Through Regulation of the Cell Cycle and DNA Damage Repair in Pancreatic Cancer Cells

Supplementary Figure Legends from Eif4b Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Abl Oncogenes

PIM3 Kinase: A Promising Novel Target in Solid Cancers

Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Data from Fimepinostat Impairs NF­κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Supplementary Figure 1 from Eif4b Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by <i>abl</i> Oncogenes

Supplementary Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma